$222 Million is the total value of Stonepine Capital Management, LLC's 19 reported holdings in Q3 2022. The portfolio turnover from Q2 2022 to Q3 2022 was 32.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| AMYT | Sell | AMRYT PHARMA PLC - SPNR ADRsponsored ads | $43,096,000 | -2.1% | 6,227,733 | -1.1% | 19.37% | -5.4% |
| Buy | QUIDELORTHO CORP | $35,857,000 | +208.0% | 501,633 | +318.8% | 16.12% | +197.6% | |
| CTIC | Buy | CTI BIOPHARMA CORP | $32,996,000 | +50.1% | 5,669,388 | +54.0% | 14.83% | +45.1% |
| Buy | XERIS BIOPHARMA HOLDINGS INC | $20,168,000 | +12.4% | 12,928,168 | +11.0% | 9.07% | +8.7% | |
| APEN | Buy | APOLLO ENDOSURGERY INC | $15,608,000 | +97.8% | 2,832,631 | +31.0% | 7.02% | +91.1% |
| ADMA | Sell | ADMA BIOLOGICS INC | $12,150,000 | -12.3% | 5,000,000 | -28.6% | 5.46% | -15.3% |
| URGN | Buy | UROGEN PHARMA LTD | $9,354,000 | +2.8% | 1,124,220 | +1.2% | 4.20% | -0.7% |
| AMRN | Sell | AMARIN CORP PLC -ADRspons adr new | $9,317,000 | -29.4% | 8,547,965 | -3.5% | 4.19% | -31.8% |
| LGND | Sell | LIGAND PHARMACEUTICALS | $8,573,000 | -4.1% | 99,562 | -0.7% | 3.85% | -7.4% |
| RZLT | Sell | REZOLUTE INC | $8,147,000 | -16.0% | 2,973,205 | -1.0% | 3.66% | -18.8% |
| OPTN | Sell | OPTINOSE INC | $7,320,000 | -23.6% | 2,000,000 | -23.6% | 3.29% | -26.1% |
| AFMD | Sell | AFFIMED NV | $4,078,000 | -53.2% | 1,979,828 | -37.0% | 1.83% | -54.8% |
| XGN | Buy | EXAGEN INC | $3,429,000 | -52.6% | 1,265,373 | +0.4% | 1.54% | -54.2% |
| CFMS | CONFORMIS INC | $3,309,000 | -45.9% | 17,304,350 | 0.0% | 1.49% | -47.8% | |
| OVID | Sell | OVID THERAPEUTICS INC | $2,835,000 | -62.2% | 1,540,671 | -55.8% | 1.27% | -63.5% |
| LIFE | Sell | ATYR PHARMA INC | $1,803,000 | +5.9% | 600,980 | -0.1% | 0.81% | +2.4% |
| OPNT | OPIANT PHARMACEUTICALS INC | $1,637,000 | -10.4% | 152,278 | 0.0% | 0.74% | -13.4% | |
| EOLS | New | EVOLUS INC | $1,610,000 | – | 200,000 | +100.0% | 0.72% | – |
| XOMA | Buy | XOMA CORP | $1,154,000 | +12.8% | 64,459 | +40.4% | 0.52% | +9.0% |
| CDTX | Exit | CIDARA THERAPEUTICS INC | $0 | – | -208,443 | -100.0% | -0.05% | – |
| SYBX | Exit | SYNLOGIC INC | $0 | – | -92,746 | -100.0% | -0.05% | – |
| ANIP | Exit | ANI PHARMACEUTICALS INC | $0 | – | -28,800 | -100.0% | -0.40% | – |
| Exit | MARINUS PHARMACEUTICALS INC | $0 | – | -242,327 | -100.0% | -0.55% | – | |
| AERI | Exit | AERIE PHARMACEUTICALS INC | $0 | – | -251,235 | -100.0% | -0.88% | – |
| DMAC | Exit | DIAMEDICA THERAPEUTICS INC | $0 | – | -1,176,344 | -100.0% | -1.10% | – |
| CSTL | Exit | CASTLE BIOSCIENCES INC | $0 | – | -295,372 | -100.0% | -3.02% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-11-10
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| CTI Biopharmap Corp. | 24 | Q1 2023 | 14.8% |
| APOLLO ENDOSURGERY INC | 23 | Q1 2023 | 15.6% |
| XOMA CORP | 20 | Q3 2023 | 5.7% |
| Cumberland Pharmaceuticals, Inc. | 19 | Q4 2020 | 7.0% |
| Amarin Corp PLC - SPONS ADR | 14 | Q3 2022 | 23.2% |
| VANDA PHARMACEUTICALS INC | 14 | Q3 2023 | 20.9% |
| BIODELIVERY SCIENCES INTL | 14 | Q1 2020 | 12.9% |
| AFFIMED NV | 13 | Q3 2022 | 7.7% |
| ALIMERA SCIENCES INC | 13 | Q3 2019 | 4.2% |
| VIVEVE MEDICAL INC | 12 | Q2 2019 | 15.3% |
View Stonepine Capital Management, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| CTI BIOPHARMA CORP | April 13, 2023 | 7,018,046 | 5.3% |
| ADMA BIOLOGICS, INC. | February 13, 2023 | 6,940,000 | 3.1% |
| Amryt Pharma plc | February 13, 2023 | 31,666,195 | 9.9% |
| Apollo Endosurgery, Inc. | February 13, 2023 | 4,351,088 | 9.0% |
| Conformis Inc | February 13, 2023 | 748,194 | 9.9% |
| Ovid Therapeutics Inc.Sold out | February 13, 2023 | 0 | 0.0% |
| Adamas Pharmaceuticals IncSold out | February 14, 2022 | 0 | 0.0% |
| CATALYST BIOSCIENCES, INC.Sold out | February 14, 2022 | 0 | 0.0% |
| Conformis Inc | February 14, 2022 | 14,768,823 | 7.9% |
| YUMANITY THERAPEUTICS, INC.Sold out | February 14, 2022 | 0 | 0.0% |
View Stonepine Capital Management, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-04-19 |
| 13F-HR | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
| SC 13G/A | 2024-02-13 |
View Stonepine Capital Management, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.